ALIM — Alimera Sciences Share News
0.000.00%
Last trade - 00:00- $301.29m
- $360.44m
- $80.75m
Alimera Sciences Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Alimera Sciences Appoints Jason Werner As Chief Operating Officer
Alimera Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Alimera Sciences, Inc. Q2 Gross Profit USD 15.113 Mln
Alimera Sciences Inc expected to post earnings of 1 cent a share - Earnings Preview
Alimera Sciences Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: Alimera Sciences Inc Files For Shelf Of Up To 49.8 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Alimera Sciences soars after Alliance Global upgrades stock to 'buy'
Brief: On June 7 Nasdaq Notified Alimera Sciences Inc Is In Compliance With Nasdaq Listing Rule 5450(B)(1)(C)
U.S. STOCKS ON THE MOVE-Nvidia, GeoVax Labs, Freshpet
Alimera Sciences up on completing enrollment in study of lead therapy
Brief: Alimera Sciences Inc-Completed Enrollment For New Day Clinical Trial, For Iluvien As Therapy In Patients Diagnosed With Diabetic Macular Edema
EyePoint Pharma sells eye disease drug to Alimera Sciences, shares rise
Brief: Alimera Acquires U.S. Commercial Rights To Yutiq®
Alimera Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Alimera Sciences Reports First Quarter 2023 Results
Alimera Sciences Inc expected to post a loss of 51 cents a share - Earnings Preview
Alimera Sciences Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Adam Morgan Reports 9.99% Stake In Alimera Sciences, As Of March 24, 2023